1. Home
  2. JAGX vs ACON Comparison

JAGX vs ACON Comparison

Compare JAGX & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • ACON
  • Stock Information
  • Founded
  • JAGX 2013
  • ACON 2008
  • Country
  • JAGX United States
  • ACON United States
  • Employees
  • JAGX N/A
  • ACON N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • ACON Retail: Computer Software & Peripheral Equipment
  • Sector
  • JAGX Health Care
  • ACON Technology
  • Exchange
  • JAGX Nasdaq
  • ACON Nasdaq
  • Market Cap
  • JAGX 3.9M
  • ACON 4.3M
  • IPO Year
  • JAGX N/A
  • ACON 2022
  • Fundamental
  • Price
  • JAGX $1.77
  • ACON $7.15
  • Analyst Decision
  • JAGX Strong Buy
  • ACON Buy
  • Analyst Count
  • JAGX 1
  • ACON 2
  • Target Price
  • JAGX $60.00
  • ACON $481.00
  • AVG Volume (30 Days)
  • JAGX 147.1K
  • ACON 9.0K
  • Earning Date
  • JAGX 08-14-2025
  • ACON 08-14-2025
  • Dividend Yield
  • JAGX N/A
  • ACON N/A
  • EPS Growth
  • JAGX N/A
  • ACON N/A
  • EPS
  • JAGX N/A
  • ACON N/A
  • Revenue
  • JAGX $11,810,000.00
  • ACON $62,948.00
  • Revenue This Year
  • JAGX $22.41
  • ACON $145.39
  • Revenue Next Year
  • JAGX $30.00
  • ACON $145.45
  • P/E Ratio
  • JAGX N/A
  • ACON N/A
  • Revenue Growth
  • JAGX 15.96
  • ACON 16.68
  • 52 Week Low
  • JAGX $1.57
  • ACON $6.20
  • 52 Week High
  • JAGX $35.25
  • ACON $3,499.51
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 39.90
  • ACON 46.50
  • Support Level
  • JAGX $1.60
  • ACON $6.82
  • Resistance Level
  • JAGX $1.70
  • ACON $7.36
  • Average True Range (ATR)
  • JAGX 0.12
  • ACON 0.35
  • MACD
  • JAGX 0.01
  • ACON 0.01
  • Stochastic Oscillator
  • JAGX 37.04
  • ACON 35.29

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Share on Social Networks: